We are very excited and grateful for being part of this amazing program!! #MassBioDrive
MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Fall 2024 Cohort last month, and are highlighting our five emerging biotech companies chosen to participate. Today, please meet RedPoint Oncology, Inc! Q: Tell us about your company and what you’re developing. What are you most excited about? A: At RedPoint, we are committed to overcoming therapy-resistant cancers by developing next-generation payloads for targeted therapies. Therapy resistance is responsible for more than 90% of cancer-related deaths, and our payloads are specifically designed to induce a form of cell death that these difficult-to-treat cancer cells are particularly vulnerable to. We are particularly excited about our potential to overcome therapy resistance, which remains one of the biggest challenges in cancer care. In addition, we are very excited about the modular nature of our payloads, which allows them to be compatible with various targeted delivery methods, enabling the generation of numerous new medicines. Q: What advice do you have for other biotech companies just getting started? A: My advice is simple: don’t be afraid to ask for help. Building a biotech startup involves navigating so many complex challenges, especially for first-time founders, and it can feel overwhelming. When I first started, I wasn’t sure where to begin or if my idea was even feasible. But by reaching out for help, even through cold outreach, I met incredible mentors who shared their knowledge and opened doors to great opportunities. Their support has been instrumental in getting RedPoint off the ground. I think we often hesitate to ask for help because we fear rejection, but I’ve found there are so many people willing to help, even if you’ve never met them before—you just have to ask. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The most impactful part would be the tremendous support system and mentorship I received from the MassBioDrive (MBD) program. I think MBD is different from many other accelerator programs as it is tailored to each of our specific needs. From building the mentor team to covering biotech-specific topics, the program offers personalized guidance. Our mentors are incredibly knowledgeable and have been so supportive throughout the process. Each week, we engage in open discussions and receive constructive feedback on our progress. I’m truly grateful for the experience! Learn more about RedPoint Oncology: https://lnkd.in/eeQTDCh6 Learn more about MassBioDrive: https://lnkd.in/eAztxEdd Mengdie Wang, PhD